Barclays PLC Kura Oncology, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

A detailed history of Barclays PLC transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Barclays PLC holds 165,484 shares of KURA stock, worth $1.49 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
165,484
Previous 165,484 -0.0%
Holding current value
$1.49 Million
Previous $3.23 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$18.57 - $23.23 $1.57 Million - $1.96 Million
84,563 Added 104.5%
165,484 $3.23 Million
Q2 2024

Aug 14, 2024
SELL
$17.53 - $22.98 $403,032 - $528,333
-22,991 Reduced 22.13%
80,921 $1.67 Million
Q1 2024

May 15, 2024
SELL
$13.42 - $23.53 $1.39 Million - $2.43 Million
-103,360 Reduced 49.87%
103,912 $2.22 Million
Q4 2023

Feb 15, 2024
BUY
$7.58 - $14.38 $394,364 - $748,148
52,027 Added 33.51%
207,272 $2.98 Million
Q3 2023

Nov 07, 2023
BUY
$8.44 - $11.86 $278,334 - $391,119
32,978 Added 26.97%
155,245 $1.42 Million
Q2 2023

Aug 03, 2023
SELL
$9.62 - $13.99 $1.01 Million - $1.47 Million
-104,848 Reduced 46.17%
122,267 $1.29 Million
Q1 2023

May 04, 2023
BUY
$10.71 - $14.6 $439,816 - $599,563
41,066 Added 22.07%
227,115 $2.78 Million
Q4 2022

Feb 13, 2023
SELL
$11.23 - $16.9 $499,656 - $751,931
-44,493 Reduced 19.3%
186,049 $2.31 Million
Q3 2022

Nov 03, 2022
BUY
$12.01 - $19.45 $1.55 Million - $2.51 Million
128,990 Added 127.02%
230,542 $3.15 Million
Q2 2022

Aug 12, 2022
BUY
$10.71 - $18.33 $418,364 - $716,024
39,063 Added 62.51%
101,552 $1.86 Million
Q1 2022

May 16, 2022
SELL
$11.78 - $16.98 $743,989 - $1.07 Million
-63,157 Reduced 50.27%
62,489 $1 Million
Q4 2021

Feb 14, 2022
BUY
$12.22 - $19.57 $521,928 - $835,854
42,711 Added 51.5%
125,646 $1.76 Million
Q3 2021

Nov 09, 2021
BUY
$15.42 - $21.72 $126,274 - $177,865
8,189 Added 10.96%
82,935 $1.55 Million
Q2 2021

Aug 13, 2021
SELL
$20.85 - $29.88 $1.28 Million - $1.84 Million
-61,456 Reduced 45.12%
74,746 $1.56 Million
Q1 2021

May 13, 2021
BUY
$24.75 - $39.14 $2.84 Million - $4.49 Million
114,698 Added 533.38%
136,202 $3.85 Million
Q4 2020

Feb 11, 2021
SELL
$29.0 - $41.62 $2.86 Million - $4.11 Million
-98,642 Reduced 82.1%
21,504 $702,000
Q3 2020

Nov 12, 2020
BUY
$16.3 - $30.64 $568,348 - $1.07 Million
34,868 Added 40.89%
120,146 $3.68 Million
Q2 2020

Aug 12, 2020
BUY
$7.95 - $18.81 $390,583 - $924,135
49,130 Added 135.91%
85,278 $1.39 Million
Q1 2020

May 13, 2020
BUY
$6.45 - $14.04 $5,953 - $12,958
923 Added 2.62%
36,148 $360,000
Q4 2019

Feb 10, 2020
BUY
$12.97 - $15.94 $235,742 - $289,725
18,176 Added 106.61%
35,225 $484,000
Q3 2019

Nov 14, 2019
SELL
$14.75 - $20.87 $68,292 - $96,628
-4,630 Reduced 21.36%
17,049 $259,000
Q2 2019

Aug 14, 2019
BUY
$14.71 - $19.79 $201,276 - $270,786
13,683 Added 171.12%
21,679 $427,000
Q1 2019

May 15, 2019
BUY
$13.73 - $16.87 $109,785 - $134,892
7,996 New
7,996 $133,000
Q4 2018

Feb 14, 2019
SELL
$10.6 - $17.49 $137,429 - $226,757
-12,965 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$16.65 - $21.85 $121,295 - $159,177
7,285 Added 128.26%
12,965 $228,000
Q2 2018

Aug 14, 2018
SELL
$14.8 - $18.8 $48,795 - $61,983
-3,297 Reduced 36.73%
5,680 $103,000
Q1 2018

May 15, 2018
BUY
$14.5 - $23.4 $52,200 - $84,240
3,600 Added 66.95%
8,977 $168,000
Q4 2017

Feb 14, 2018
BUY
$13.5 - $16.65 $66,528 - $82,051
4,928 Added 1097.55%
5,377 $82,000
Q3 2017

Nov 14, 2017
BUY
$6.05 - $14.95 $2,716 - $6,712
449
449 $7,000

Others Institutions Holding KURA

# of Institutions
185
Shares Held
81.8M
Call Options Held
42.1K
Put Options Held
34K
View Full List

About Kura Oncology, Inc.

KURA Quotes by TradingView
  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $603M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email